Tirofiban With Acute Myocar Dial Infarction Undergoing Emergency Percutaneous Coronary Intervention Therapy

Objective Acute myocardial infarction has become a major threat to human health disease, clinical common treatment is the emergency percutaneous coronary intervention, but the thrombus formation resulted from the aggregation of platelets affects treatment effect, Hydrochloric Acid Tirofiban is capable for blocking last access initiation of platelet aggregation. Therefore, it is necessary to investigate application efficacy of Tirofiban on patients with myocardial infarction undergoing emergency percutaneous coronary intervention therapy to improve the success rate of intervention treatment and prognosis, and the life quality of patients and reduce the incidence and mortality of adverse events.Methods Ninety eight patients with acute myocardial infarction were selected as research subjects, who were defined into the control group and the observation group on the basis of different solutions of clinical treatment, patients in the observation group served Tirofiban in the coronary artery before the access initiation of the culprit vessel, and patients in the control group regularly served Tirofiban, the incidence of reoccurrence of acute myocardial infarction and severe angina of patients in two groups during hospitalization was observed, the occurrence of adverse events of patients with thrombocytopenia in two groups were compared, the number of platelets of patients in two groups was determined, comparative analysis was conducted, and therapeutic effects on patients in two groups were evaluated.Results The comparison in general conditions, TIM blood flow condition, infarction related blood vessels, lesion blood vessel counts of patients in two groups before treatment satisfied p > 0.05, the differences were not statistically significant. The comparison in the platelet count, bleeding complications and other complications of patients after treatment satisfied p > 0.05, and the differences were not statistically significant. The incidence of adverse cardiovascular events of patients in the observation group hit 4.1%, the control group, and that value of patients in the control group hit 18.4%, the incidence of adverse cardiovascular events of patients in the observation group was obviously lower than that of patients in the control group, the comparison in total adverse cardiovascular events of patients in two groups satisfied p < 0.05, and the difference was statistically significant. The comparisons in instant TIMI flow conditions, TIMI flow condition in 30 minutes and left ventricular ejection fraction of patients in the observation group and that of patients in the control group patients satisfied p < 0.05, and the differences were statistically significant.Conclusions Tirofiban plays an important role on patient with acute myocardial infarction undergoing emergency percutaneous coronary intervention therapy, the administration of Tirofiban in coronary artery before the access initiation of culprit vessel can improve microcirculation, the success rate of intervention treatment, prognosis and the survival quality, reduce the incidence of adverse cardiovascular events without increasing bleeding incident, thrombocytopenia and the occurrence of adverse reactions, being safe and reliable.